
China Pharma Holdings CPHI
€ 0.53
-3.05%
Geschäftsbericht 2025
hinzugefügt 01.04.2026
China Pharma Holdings Kurzfristige Verbindlichkeiten 2011-2026 | CPHI
Kurzfristige Verbindlichkeiten Jährlich China Pharma Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.4 M | 5.02 M | 6.82 M | 12.7 M | 10.5 M | 11.4 M | 10 M | 10.1 M | 9.23 M | 10.4 M | 12.8 M | 14.2 M | 12 M | 14.6 M | 13.8 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 14.6 M | 5.02 M | 10.7 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Arzneimittelhersteller
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
3.81 M | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
20.8 M | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
11.4 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
125 M | - | - | $ 754 M | ||
|
Catalent
CTLT
|
1.03 B | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
111 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
539 M | - | - | $ 28.9 M | ||
|
DURECT Corporation
DRRX
|
27 M | - | - | $ 50.1 M | ||
|
Alimera Sciences
ALIM
|
21.9 M | - | - | $ 142 M | ||
|
Athenex
ATNX
|
115 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
48.8 M | - | - | $ 2.06 B | ||
|
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
31.6 M | $ 3.27 | 4.81 % | $ 46 M | ||
|
Bausch Health Companies
BHC
|
4.3 B | $ 5.75 | 0.35 % | $ 2.1 B | ||
|
Harrow Health
HROW
|
96.3 M | $ 38.24 | 3.07 % | $ 1.41 B | ||
|
Canopy Growth Corporation
CGC
|
94.4 M | $ 1.09 | 0.46 % | $ 117 M | ||
|
Jupiter Wellness
JUPW
|
5.98 M | - | - | $ 33.6 M | ||
|
Lannett Company
LCI
|
105 M | - | 1.15 % | $ 7.11 M | ||
|
Neoleukin Therapeutics
NLTX
|
16.4 M | - | - | $ 193 M | ||
|
Evolus
EOLS
|
75.3 M | $ 4.38 | 1.15 % | $ 282 M | ||
|
Emergent BioSolutions
EBS
|
651 M | $ 8.66 | 5.1 % | $ 443 M | ||
|
Tilray
TLRY
|
433 M | $ 6.9 | 2.6 % | $ 4.26 B | ||
|
Organogenesis Holdings
ORGO
|
77.5 M | $ 2.49 | 4.41 % | $ 328 M | ||
|
Pacira BioSciences
PCRX
|
310 M | $ 24.0 | -0.25 % | $ 1.11 B | ||
|
Veru
VERU
|
11.9 M | $ 2.38 | 0.11 % | $ 321 M | ||
|
PetIQ
PETQ
|
190 M | - | 1.64 % | $ 400 M | ||
|
Viatris
VTRS
|
6.75 B | $ 13.96 | 0.9 % | $ 16.8 B | ||
|
ProPhase Labs
PRPH
|
16.1 M | - | - | $ 5.07 M | ||
|
Relmada Therapeutics
RLMD
|
6.43 M | $ 7.36 | -0.34 % | $ 291 M | ||
|
Assertio Holdings
ASRT
|
128 M | $ 18.02 | 0.03 % | $ 115 M | ||
|
Radius Health
RDUS
|
94.8 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
50 M | - | -4.76 % | $ 65.3 M | ||
|
cbdMD
YCBD
|
8.62 M | $ 0.72 | -3.36 % | $ 3.11 M | ||
|
OptiNose
OPTN
|
177 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
5.73 M | $ 1.02 | 0.99 % | $ 50.9 M | ||
|
PLx Pharma
PLXP
|
11.9 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
33.5 M | $ 8.4 | 0.12 % | $ 735 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
4.1 M | $ 2.29 | -2.71 % | $ 2.84 M | ||
|
Zomedica Corp.
ZOM
|
9.45 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
9.17 M | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
9.58 M | $ 0.91 | -3.12 % | $ 32.7 M | ||
|
Tricida
TCDA
|
29.5 M | - | - | $ 3.25 M | ||
|
TherapeuticsMD
TXMD
|
4.78 M | $ 2.09 | 1.96 % | $ 24.2 M |